Plain-English translation of NCT04260022 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a new medication called HQP1351 can help people whose leukemia has stopped responding to standard treatments. The study will test three different doses of the medication taken by mouth every other day, and will also test whether combining this medication with another drug called works better for certain patients. Researchers will measure how well the medication works, how safe it is, and how your body processes it.
Many people with chronic myeloid leukemia and acute lymphoblastic leukemia eventually develop resistance to the current standard treatments, meaning those drugs stop working. This trial exists to find out whether this new medication can help patients whose cancers have become resistant or intolerant to other available drugs.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take the medication at one of three dose levels by mouth every other day for cycles of 28 days. You'll come to the clinic regularly for blood draws to check how your blood counts are doing, how the medication is working, and how your body is processing the drug. The study team will closely monitor you during your first month to make sure the medication is safe at your assigned dose. Depending on which part of the study you're in, you may take the medication alone or combined with another drug.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States